natgillin/translations-raw huggingface dataset:
Serum ALT and HBV DNA levels should be followed regularly after treatment discontinuation to detect any late virological relapse. 
Po prenehanju zdravljenja je treba redno kontrolirati koncentracijo ALT in HBV DNA v serumu, da bi odkrili morebiten pozni virološki relaps.
HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy. 
Z razširitvijo zdravljenja so bile odkrite podskupine virusa HBV (YMDD mutant HBV) z zmanjšano občutljivostjo za lamivudin.
Contains amongst others: sugar (sucrose), preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) 
Med drugim vsebuje tudi: sladkor (saharoza), konzervansa: metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216).
Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. 
Študije pri bolnikih z oslabljenim delovanjem ledvic kažejo, da renalna disfunkcija prizadene izločanje lamivudina.
In patients with YMDD mutant HBV, 41/82 (50 %) patients had improvement in liver inflammation and 40/56 (71 %) patients without YMDD mutant HBV had improvement. 
Pri 41/82 (50 %) bolnikov z YMDD mutantom HBV in pri 40/56 (71 %) bolnikov brez YMDD mutanta HBV je prišlo do izboljšanja vnetnih sprememb jeter.
Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA. 
Po prekinitvi zdravljenja hepatitisa B so opažali akutno poslabšanje hepatitisa, po navadi ugotovljeno z zvišanjem serumske ALT in ponovnim pojavom HBV DNA.
Any child exposed in utero to nucleoside and nucleotide analogues, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in cases which have relevant signs or symptoms. 
Vsakega otroka, ki je in utero izpostavljen nukleozidnim ali nukleotidnim analogom, je treba klinično in laboratorijsko spremljati.
Data available in patients undergoing intermittent haemodialysis (for less than or equal to 4 hrs dialysis 2-3 times weekly), indicate that following the initial dosage reduction of lamivudine to correct for the patient's creatinine clearance, no further dosage adjustments are required while undergoing dialysis. 
do 3-krat tedensko), kažejo, da po začetnem zmanjšanju odmerka lamivudina in korekciji glede na bolnikov očistek kreatinina nadaljnje uravnave odmerka med dializo niso potrebne.
A common side effect which may show up in blood tests is: 
Pogost neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je:
Lamivudine has no pharmacokinetic interaction with alpha-interferon when the two medicinal products are concurrently administered. 
V primeru sočasne uporabe obeh zdravil lamivudin nima farmakokinetičnih interakcij z interferonom alfa.
ALT  3 x baseline value† 
ALT ≥ 2 x osnovna vrednost ALT ≥ 3 x osnovna vrednost†
A very rare side effect (these may affect up to 1 in 10,000 people) is: 
Zelo redek neželeni učinek (pojavi se lahko pri največ 1 od 10.000 bolnikov) je:
In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min. 
Pri starejših bolnikih normalen proces staranja s spremljajočim upadanjem ledvične funkcije nima klinično pomembnega učinka na izpostavljenost lamivudinu, razen pri bolnikih z očistkom kreatinina
The active substance is lamivudine. 
Učinkovina je lamivudin.
Stop taking Zeffix. 
Nehajte jemati zdravilo Zeffix.
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. 
Sočasna uporaba raztopine sorbitola (3,2 g; 10,2 g ; 13,4 g) z enkratnim odmerkom 300 mg (dnevni odmerek za odrasle z virusom HIV) lamivudina v peroralni raztopini, je pri odraslih povzročila od količine sorbitola odvisno zmanjšanje izpostavljenosti (AUC∞) lamivudinu za 14 %, 32 % oziroma 36 % ter zmanjšanje Cmax lamivudina za 28 %, 52 % in 55 %.
In patients who have YMDD mutant HBV, a switch to or addition of an alternative agent without cross-resistance to lamivudine based on therapeutic guideline should be considered (see section 5.1). 
Pri bolnikih z YMDD mutantom HBV je treba skladno s smernicami za zdravljenje razmisliti o zamenjavi ali dodatku drugega zdravila, ki nima navzkrižne odpornosti proti lamivudinu (glejte poglavje 5.1).
Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com 
GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 finland.tuoteinfo@gsk.com
Your doctor may prescribe a lower dose if you have problems with your kidneys. 
Če imate težave z ledvicami, vam bo zdravnik morda predpisal nižji odmerek.
How to take Zeffix 
Kako jemati zdravilo Zeffix
Improvement in bridging fibrosis occurred in 19/30 (63 %) patients without YMDD mutant and 22/44 (50 %) patients with the mutant. 
Pri 19/30 (63 %) bolnikov brez YMDD mutanta in 22/44 (50 %) bolnikov z mutantom je prišlo do izboljšanja fibroze.
In patients without YMDD mutant HBV, 14/22 (64 %) showed improvement in necroinflammatory score and 1/22 (5 %) patients worsened compared to pre-treatment. 
Pri bolnikih brez YMDD mutanta HBV se je pri 14/22 (64 %) pokazalo izboljšanje nekroznih in vnetnih sprememb, pri 1/22 (5 %) pa se je stanje v primerjavi s stanjem pred zdravljenjem poslabšalo.
Immunosuppressive treatments 
Bolezni imunskega sistema
Blood and lymphatic system disorders Not known 
Bolezni krvi in limfatičnega sistema:
Addition of 10 mg adefovir dipivoxil once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml. 
52-tedensko zdravljenje z lamivudinom v odmerku 100 mg in dodatkom 10 mg adefovirjevega dipivoksila enkrat dnevno je vrednosti HBV DNA v povprečju zmanjšalo za 4,6 log10 kopij/ml.
Don't stop taking Zeffix 
Ne prenehajte jemati zdravila Zeffix
Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (less than 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age. 
(manj kot 4 % koncentracije v materinem serumu) in se progresivno zmanjša do nezaznavne ravni, ko dojenček doseže 24 tednov starosti.
Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine. 
Po prekinitvi zdravljenja z lamivudinom po serokonverziji HBeAg sta serološki odziv in klinična remisija običajno stanovitna.
Do not stop treatment with Zeffix without your doctor's advice. 
Ne prekinjajte zdravljenja z zdravilom Zeffix, ne da bi se prej posvetovali z zdravnikom.
Exacerbations on treatment 
Trajanje zdravljenja
Experience in patients with HBeAg positive CHB and compensated liver disease In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication [34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)}, normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 1618 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis. 
Izkušnje pri HBeAg pozitivnih bolnikih s CHB in kompenzirano jetrno boleznijo V nadzorovanih študijah je enoletno zdravljenje z lamivudinom znatno zavrlo replikacijo HBV DNA [pri 34 do 57 % bolnikov je bila pod mejo dokazljivosti s testom (Abbott Genostics hibridizacijski test v raztopini, LLOD < 1,6 pg/ml)], normaliziralo aktivnost ALT (pri 40 do 72 % bolnikov), sprožilo serokonverzijo HBeAg (izginotje HBeAg ter pojav protiteles HBeAb z izginotjem HBV DNA [z običajnimi testi] pri 16 do 18 % bolnikov), izboljšalo histološko sliko (pri 38 do 52 % bolnikov se je Knodell-ov histološki indeks aktivnosti [HAI] znižal za ≥ 2 točki) in zmanjšalo progresijo fibroze (pri 3 do 17 % bolnikov) in progresijo v cirozo.
In patients with the mutant, 4/26 (15%) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pretreatment. 
Pri bolnikih z YMDD mutantom se je pri 4/26 (15 %) pokazalo izboljšanje nekroznih in vnetnih sprememb, pri 8/26 (31 %) bolnikih pa se je stanje v primerjavi s stanjem pred zdravljenjem poslabšalo.
Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60 % chance of developing the YMDD mutant compared with 8 % of those with HBV DNA levels less than 200 copies/mL at 24 weeks of lamivudine therapy. 
Tisti, ki so imeli po 6 mesecih (24 tednih) zdravljenja z lamivudinom koncentracijo HBV DNA večjo kot 200 kopij/ml, so imeli 60 % možnost za pojav mutanta YMDD, v primerjavi z 8 % možnostjo pojava pri tistih, s koncentracijo HBV DNA manj kot 200 kopij/ml po 24 tednih, medtem ko je bila ta možnost v primeru koncentracije HBV DNA manj kot 1000 kopij/ml 13 % po 24 tednih zdravljenja s lamivudinom (NUCB3009 in NUCB3018).
The clinical status of the patient and the adverse reaction profile of lamivudine should be borne in mind when considering the patient's ability to drive or operate machinery. 
Pri ocenjevanju bolnikove sposobnosti za upravljanje vozil ali strojev je potrebno upoštevati klinično stanje bolnika in profil neželenih učinkov lamivudina.
An oral solution of Zeffix is available for people who need a lower than usual dose, or who can't take tablets. 
Za osebe, ki potrebujejo manjši odmerek od običajnega ali ne morejo jemati tablet, je na voljo peroralna raztopina zdravila
* Zeffix oral solution containing 5 mg/ml lamivudine. 
* Zdravilo Zeffix peroralna raztopina vsebuje 5 mg/ml lamivudina.
If you are diabetic, please note that each dose of Zeffix (100 mg = 20 ml) contains 4 g of sucrose. 
Če ste sladkorni bolnik, prosimo upoštevajte, da vsak odmerek zdravila Zeffix (100 mg = 20 ml)
You need to keep taking it every day to control your infection and stop your illness getting worse. 
Zdravilo Zeffix pomaga nadzorovati vašo okužbo s hepatitisom B. Jemati ga morate vsak dan, da bo vaša okužba kontrolirana in da se vaša bolezen ne bo slabšala.
Do not store above 25 ºC. 
Shranjujte pri temperaturi do 25 ºC.
Limited data in patients undergoing liver transplantation show that impairment of hepatic function does not impact significantly on the pharmacokinetics of lamivudine unless accompanied by renal dysfunction. 
Omejeni podatki pri bolnikih s transplantacijo jeter kažejo, da farmakokinetika lamivudina pri oslabljeni jetrni funkciji ni znatno prizadeta, vendar slednje ne velja pri sočasni ledvični disfunkciji.
However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food. 
Sočasno jemanje lamivudina s hrano ima za posledico zakasnitev tmax in zmanjšanje Cmax (zmanjšanje za do 47 %), vendar na obseg (na osnovi AUC) absorpcije lamivudina ne vpliva, torej se lamivudin lahko daje s hrano ali brez nje.
ALT  2 x baseline value and absolute ALT > 500 IU/l 
ALT ≥ 2 x osnovna vrednost in absolutni ALT
Don't store above 25 °C. 
Shranjujte pri temperaturi do 25 °C.
 Use a condom when you have oral or penetrative sex.  Don't risk blood transfer - for example, don't share needles. 
 Ne tvegajte okužbe s krvjo - na primer ne uporabljajte injekcijskih igel skupaj z drugimi.
For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of lamivudine treatment. 
O koristih ponovne uvedbe zdravljenja z lamivudinom pri bolnikih, ki se jim po zdravljenju pojavijo znaki ponovnega hepatitisa, ni dovolj podatkov.
Zeffix 100 mg film-coated tablets lamivudine 
Zeffix 100 mg filmsko obložene tablete lamivudin
Experience in CHB patients with advanced fibrosis or cirrhosis In a placebo-controlled study in 651 patients with clinically compensated chronic hepatitis B and histologically confirmed fibrosis or cirrhosis, lamivudine treatment (median duration 32 months) significantly reduced the rate of overall disease progression (34/436, 7.8 % for lamivudine versus 38/215, 17.7 % for placebo, p=0.001), demonstrated by a significant reduction in the proportion of patients having increased Child-Pugh scores (15/436, 3.4 % versus 19/215, 8.8 %, p=0.023) or developing hepatocellular carcinoma (17/436, 3.9 % versus 16/215, 7.4 %, p=0.047). 
mesecev) pomembno zmanjšalo odstotek celokupnega napredovanja bolezni (pri 34/436 oz. 7,8 % bolnikov, ki so se zdravili z lamivudinom, v primerjavi z 38/215 oz. 17,7 % bolnikov, ki so prejemali placebo, p=0,001), kar se je kazalo kot značilno zmanjšanje odstotka bolnikov, pri katerih se je povečal Child-Pugh-jev indeks (15/436 oz. 3,4 % v primerjavi z 19/215 oz. 8,8 %, p=0,023) ali pri katerih se je razvil hepatocelularni karcinom (17/436 oz. 3,9 % v primerjavi z 16/215 oz. 7,4 %, p=0,047).
Patients categorised as non-YMDD mutant were those with > 95% wild-type HBV at all annual time-points during the 5-year study period 
Bolniki z YMDD mutantom so bolniki, ki so v obdobju 5-ih let imeli v kateremkoli časovnem obdobju ≥ 5 % YMDD mutana HBV. Bolniki brez YMDD mutanta so bolniki, ki so med 5 letnim trajanjem študije v vseh časovnih obdobjih imeli ≥ 95 % divjega tipa HBV.
There were no observed clinically significant adverse interactions in patients taking lamivudine concurrently with commonly used immunosuppressant medicinal products (e.g. cyclosporin A). 
Pri bolnikih, ki so sočasno jemali lamivudin in pogosto uporabljana imunosupresivna zdravila (npr. ciklosporin A), ni bilo opaznih klinično pomembnih neželenih interakcij.
Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline. 
Spontana poslabšanja kroničnega hepatitisa B so razmeroma pogosta; značilna zanje so prehodna zvišanja serumske ALT.
Experience in patients with HBeAg positive CHB and compensated liver disease In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication (34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)], normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 1618 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis. 
Izkušnje pri HBeAg pozitivnih bolnikih s CHB in kompenzirano jetrno boleznijo V nadzorovanih študijah je enoletno zdravljenje z lamivudinom znatno zavrlo replikacijo HBV DNA [pri 34 do 57 % bolnikov je bila pod mejo dokazljivosti s testom (Abbott Genostics hibridizacijski test v raztopini, LLOD < 1,6 pg/ml)], normaliziralo aktivnost ALT (pri 40 do 72 % bolnikov), sprožilo serokonverzijo HBeAg (izginotje HBeAg ter pojav protiteles HBeAb z izginotjem HBV DNA [z običajnimi testi] pri 16 do 18 % bolnikov), izboljšalo histološko sliko (pri 38 do 52 % bolnikov se je
- Baseline 3 
- Izhodiščna vrednost3
• if you're allergic to lamivudine or to any of the other ingredients of this medicine (listed in Section 6). 
• če ste alergični na lamivudin ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju Posvetujte se z zdravnikom, če mislite, da to velja za vas.
A common side effect (these may affect up to 1 in 10 people) is: 
Pogost neželeni učinek (pojavi se lahko pri največ 1 od 10 bolnikov) je:
The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance. 
Zaradi omejene presnove in vezave na plazemske proteine ter skoraj popolnega izločanja nespremenjene učinkovine skozi ledvice je verjetnost presnovnih interakcij nizka.
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance. 
Zaradi zmanjšanega očistka pri bolnikih z zmernim do hudo oslabljenim delovanjem ledvic so serumske koncentracije (AUC) lamivudina zvečane.
For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B. 
Med zdravljenjem kroničnega hepatitisa B samo z lamivudinom pri bolnikih, ki so sočasno okuženi z virusom HIV in odklanjajo protiretrovirusno zdravljenje, obstaja tveganje za mutacijo virusa HIV.
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. 
Posledica tega je možno tveganje za neučinkovitost kladribina v primeru kombinirane klinične uporabe.
Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see section decompensated liver disease in combination with a second agent, without cross-resistance to lamivudine (see section 4.2). 
Začetek zdravljenja z lamivudinom pride v upoštev le, kadar uporaba drugega protivirusnega zdravila z višjo genetsko pregrado proti odpornosti ni na razpolago oz. ni primerna (glejte poglavje 5.1).
Don't store above 30 °C. 
Shranjujte pri temperaturi do 30 °C.
First dose of Zeffix oral solution * 
Zeffix peroralne raztopine *
Sucrose (20 % w/v) Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Citric acid (anhydrous) Propylene glycol 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi saharoza (20 % w/v) metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) citronska kislina (brezvodna) propilenglikol natrijev citrat umetna aroma jagode umetna aroma banane prečiščena voda
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Zeffix. 
Če dojite, ali razmišljate o dojenju: se posvetujte z zdravnikom, preden vzamete zdravilo Zeffix.
- Baseline normal above normal 
- Izhodiščna vrednost normalna vrednost vrednost višja od normalne vrednosti
In patients without the mutant, 20/27 (74 %) had improvements in necroinflammatory activity and 2/27 (7 %) had worsening. 
Pri bolnikih brez YMDD mutanta je prišlo do izboljšanja nekrotičnih in vnetnih sprememb pri 20/27 (74 %) bolnikov, do poslabšanja pa pri 2/27 (7 %) bolnikov.
Excipient intolerance 
Intoleranca na pomožne snovi
Consider more frequent monitoring of HBV viral load when chronic co-administration cannot be avoided. 
Če pa se kronični sočasni uporabi ni mogoče izogniti, pogosteje kontrolirajte virusno breme HIV-1.
Zeffix 5 mg/ml oral solution lamivudine 
Zeffix 5 mg/ml peroralna raztopina lamivudin
In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects. 
39 % oseb prišlo do poznega virusnega relapsa.
There is no information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine. 
Pri nosečnicah, ki se zdravijo z lamivudinom, je malo podatkov o prenosu virusa hepatitisa B z matere na plod.
Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment. 
Na osnovi teh podatkov pri bolnikih z jetrno okvaro, razen v primeru sočasnega oslabljenega delovanja ledvic, odmerka ni treba prilagajati.
If you get any side effects, talk to your doctor or pharmacist. 
- Če opazite katerikoli neželeni učinek, se posvetujte s svojim zdravnikom ali farmacevtom.
• cladribine, used to treat hairy cell leukaemia Tell your doctor if you're being treated with any of these. 
• kladribin, ki se uporablja pri zdravljenju dlakastocelične levkemije.
You must not stop taking Zeffix without consulting your doctor. 
Ne prenehajte z jemanjem zdravila Zeffix, če se o tem predhodno niste posvetovali z zdravnikom.
How to store Zeffix 
Shranjevanje zdravila Zeffix
Exacerbations of hepatitis 
Poslabšanja hepatitisa Poslabšanja med zdravljenjem
PHARMACEUTICAL FORM AND CONTENTS Each bottle contains 240 ml oral solution 
Ena plastenka vsebuje 240 ml peroralne raztopine
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR ORAL SOLUTION 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA ZA PERORALNO RAZTOPINO
of patients with pre-treatment ALT > 2 x ULN seroconverted. 
- Bolniki z izhodiščno vrednostjo ALT ≤ 1 x ZMN2 - Bolniki z izhodiščno vrednostjo ALT > 2 x ZMN
NAME OF THE MEDICINAL PRODUCT Zeffix 5 mg/ml oral solution Lamivudine 
Navodilo za uporabo Zeffix 5 mg/ml peroralna raztopina lamivudin
Each ml of oral solution contains 5 mg of lamivudine. 
Vsak ml peroralne raztopine vsebuje 5 mg lamivudina.
Each ml of the oral solution contains 5 mg lamivudine 
En ml peroralne raztopine vsebuje 5 mg lamivudina
NAME OF THE MEDICINAL PRODUCT Zeffix 100 mg film-coated tablets Lamivudine 
Navodilo za uporabo Zeffix 100 mg filmsko obložene tablete lamivudin
The oral solution contains propyl and methyl parahydroxybenzoate. 
Peroralna raztopina vsebuje propilparahidroksibenzoat in metilparahidroksibenzoat, ki lahko pri posameznikih povzročita alergijsko reakcijo.
If you get any side effects Talk to your doctor or pharmacist. 
Če se vam pojavi kakšen neželeni učinek se posvetujte s svojim zdravnikom ali farmacevtom.
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels. 
(tirozin-metionin-aspartat-aspartat) mutanta HBV zmanjša terapevtski odziv na lamivudin; to se kaže s porastom HBV-DNA in ALT v primerjavi s predhodnimi ravnmi med zdravljenjem.
Always take this medicine exactly as your doctor has told you to. 
Pri jemanju tega zdravila natančno upoštevajte zdravnikova navodila.
• difficulty swallowing or breathing Contact a doctor immediately if you get these symptoms. 
Nemudoma se posvetujte z zdravnikom, če se vam pojavijo ti simptomi.
EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PROMET Z ZDRAVILOM
Talk to your doctor or pharmacist. 
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom.
NAME OF THE MEDICINAL PRODUCT Zeffix 100 mg film-coated tablets 
Zeffix 100 mg filmsko obložene tablete
The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10 %) extent of hepatic metabolism and the low plasma protein binding. 
obsega jetrne presnove in majhne vezave na plazemske proteine je verjetnost interakcij presnovnih substanc z lamivudinom majhna.
Polysorbate 80 
NUCB3018
Tabulated list of adverse reactions 
Prikaz neželenih učinkov v preglednici
Zeffix contains sucrose. 
Zeffix peroralne raztopine
PHARMACEUTICAL FORM Oral solution 
SEZNAM POMOŽNIH SNOVI FARMACEVTSKA OBLIKA IN VSEBINA
The pharmacokinetics of lamivudine are unaffected by hepatic impairment. 
Pri oslabljenem delovanju jeter ostane farmakokinetika lamivudina nespremenjena.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 28 tablet box, 84 tablet box 
škatla z 28 tabletami, škatla s 84 tabletami
This summary was last updated in December 2012. 
Povzetek je bil nazadnje posodobljen decembra 2012.
The European Commission granted a marketing authorisation valid throughout the European Union, for Prac-tic to on 18 December 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Prac-tic, veljavno po vsej Evropski uniji, odobrila dne 18. decembra 2006.
Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children. 
Nedavno zdravljene živali ne smejo spati v isti postelji s svojimi lastniki, zlasti ne z otroki.